Cochrane COVID-19 Study Register
Study record
NCT05043246First Published: 2021 Sep 14Updated Date: 2021 Sep 14

Safety and Immune Response of COVID-19 Vaccination in Middle-aged and Elderly Patients With Basic Disease

  1. Study Type
  2. Observational
  1. Study Aim
  2. Prevention
  1. Study Design
  2. Case series/Case control/Cohort
  1. Intervention Assignment
  2. Not Applicable
Reference record

Safety and Immune Response of COVID-19 Vaccination in Middle-aged and Elderly Patients With Basic Disease

NCT05043246
Trial registry record
No Results
On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SARS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19).Due to the decline of immunity and cardiopulmonary function in the middle-aged and elderly, COVID-19 's severe illness and mortality mainly occur in the middle-aged and elderly over the age of 60, especially those with basic diseases (hypertension, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, etc.). Vaccination of COVID-19 vaccine can effectively prevent COVID-19 virus infection and delay or prevent patients from developing into critical illness and reduce mortality.To evaluate the safety and effectiveness of the population vaccinated with COVID-19 vaccine, and to play a scientific and theoretical supporting role in guiding COVID-19 vaccination scientifically, reasonably and effectively, so this study was carried out